A powerful new prostate cancer treatment from
IsoRay Medical, innovators in
seed brachytherapy and
medical radioisotope
applications.

Cesium-131 is the most significant scientific advancement in prostate cancer brachytherapy in more than 20 years.

Cesium-131 provides doctors and patients a powerful new treatment option in prostate seed brachytherapy.

Compare the clinical benefits of Cesium-131:

Cesium-131 has a higher energy and shorter half-life* than either Iodine-125 or Palladium-103. Early data suggests these characteristics can be attributed to Cesium-131's tolerability and relatively rapid resolution of commonly seen urinary side effects.¹

Isotope	Half-Life	Energy	90% Delivered	Total Radiation to tumor
Cesium-131	9.7 days	30.4 Kev	33 days	115 Gy
Palladium-103	17 days	20.8 Kev	58 days	125 Gy
Iodine-125	60 days	28.5 Kev	204 days	145 Gy

Prestidge B.R., Bice W.S., Jurkovic I., et al. Cesium-131 Permanent Prostate Brachytherapy: An Initial Report. Int. J. Radiation Oncology Biol. Phys. 2005; 63 (1): 5336-5337.
Chen, Z., Dose rate constant of a Cesium-131 interstitial brachytherapy seed measured by thermoluminescent dosimetry and gamma-ray spectrometry: Medical Physics. 32 (11), November 2005.

* Compared to other isotopes commonly used in permanent seed brachytherapy for prostate cancer

Ask your doctor why Cesium-131 could be a better treatment choice for your prostate cancer.

Site Map